Pravastatin: Your brand is changing

Brand change Active

Between 1 December 2023 and 1 May 2024, your brand of pravastatin will be changing from Mylan or Viatris Pravastatin to Clinect Pravastatin.

What's changing?

Your brand of pravastatin will be changing from Mylan or Viatris Pravastatin to Clinect Pravastatin. Your tablet will look different and the packaging will change, but the medicine will work the same.

Key differences:

  • Shape - the new tablets are round
  • Colour - the 40 mg tablets are green
  • Lettering - the Clinect tablets have APO on one side and PRA with the strength on the other (20 or 40)

Medicines can look different, it's what's inside that's important [PDF, 403 KB]

Side by side comparison of tablet shapes. The viatris/mylan tablets are square with rounded edges and are the same sandy colour. The Clinect tablets are round, the 40 mg is green. .
Pravastatin tablets

Clinect Pravastatin works the same way

Clinect Pravastatin contains the same active ingredient in the same quantities as the Mylan and Viatris tablets. It will work in your body the same way. 

Medsafe has assessed the Clinect brand for safety, effectiveness, and quality. It meets the same standards as the Mylan and Viatris brands. It is approved for use in New Zealand.

Clinect Pravastatin Datasheet [PDF] - Medsafe(external link)

Clinect Pravastatin Customer Information Sheet [PDF] - Medsafe(external link)

Key dates

You might be changed to your new brand any time between 1 December 2023 and 1 May 2024. 

1 December 2023 - Clinect Pravastatin 20 mg and 40 mg are funded

1 January 2024 - Pravastatin Mylan Tab 20 mg no longer funded

1 May 2024 - Pravastatin Viatris 20 mg and Pravastatin Mylan 40 mg no longer funded 

Why is this happening?

Pharmac runs an annual tender on many of the medicines we fund. This tender gives suppliers an opportunity to offer already funded products for better, more competitive prices. The savings we make through the tender process frees up money so we can fund new treatments for people.

Following a recent tender, we made the decision to change to the Clinect brand. Both the previous brands, Mylan and Viatris, were supplied by Viatris.

This brand change is helping us fund more medicines for better health outcomes for all New Zealanders.

About the Annual Tender

Who to contact

If you have any questions about this change, talk to your pharmacist or the person who prescribes your pravastatin. They know you and your clinical history, they can offer you the best advice. 

If you have funding questions about this change or other treatments, email enquiry@pharmac.govt.nz